Thymosin Alpha-1: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 14 sources cited
Overview
Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide naturally produced by the thymus gland that serves as a master regulator of immune function. It is one of the most clinically validated immunomodulatory peptides, approved in over 35 countries for the treatment of hepatitis B, hepatitis C, and as an immune adjuvant. Marketed as Zadaxin, it was the subject of a 2024 review covering more than 30 clinical trials and over 11,000 participants. Tα1 enhances both innate and adaptive immunity while maintaining immune homeostasis — stimulating underactive immune systems without over-activating already functional ones, a property that distinguishes it from crude immunostimulants.
Mechanism of Action
Thymosin Alpha-1 acts as an endogenous immune regulator through multiple interconnected mechanisms. At the level of the innate immune system, Tα1 activates toll-like receptors (TLR2, TLR9) on dendritic cells and macrophages, enhancing pathogen recognition and antigen presentation. It stimulates natural killer (NK) cell cytotoxicity, increasing the first-line defense against virally-infected and malignant cells. Tα1 promotes the maturation and differentiation of dendritic cells, the professional antigen-presenting cells that bridge innate and adaptive immunity. In the adaptive immune system, Tα1 drives T-cell maturation from thymic progenitors, increases CD4+ and CD8+ T-cell populations, and enhances T-cell receptor diversity. It promotes the Th1 immune response (interferon-gamma, IL-2, IL-12) over the Th2 response, shifting immunity toward cellular defense — crucial for fighting intracellular pathogens and tumors. Simultaneously, it enhances the function of regulatory T cells (Tregs), preventing excessive inflammation and autoimmune responses. This bidirectional modulation — stimulating underactive immunity while restraining overactive responses — is Tα1's most remarkable property. At the molecular level, Tα1 activates the p38 MAPK signaling pathway and the IRF (interferon regulatory factor) family of transcription factors, increasing the expression of MHC class I molecules and co-stimulatory molecules on antigen-presenting cells. It also enhances antibody responses to vaccines by improving B-cell activation and class switching. In cancer immunology, Tα1 restores T-cell function in the immunosuppressive tumor microenvironment and has shown synergy with checkpoint inhibitors and chemotherapy in preclinical models.
Thymosin Alpha-1 Benefits: What the Research Shows
- A 2011 meta-analysis of 7 RCTs (535 patients) found Tα1 combined with interferon-alpha improved HBV DNA clearance and HBeAg loss in chronic hepatitis B compared to interferon alone; a 2026 Cochrane review of 10 trials rated the evidence for Tα1 in hepatitis B as low to very low certainty
- Goldstein and Goldstein (2009, Expert Opinion on Biological Therapy) reviewed Tα1's clinical use in hepatitis B and C, cancer, sepsis and other infections, and as a vaccine adjuvant
- A Phase II randomized trial in unresectable hepatocellular carcinoma (25 patients) found numerically longer survival with Tα1 plus transcatheter arterial chemoembolization than with TACE alone, but the difference was not statistically significant
- Romani et al. (2004, Blood) demonstrated Tα1 activated dendritic cells through toll-like receptor signaling, increasing IL-12 production
- Retrospective Chinese hospital cohorts during the COVID-19 pandemic (2020–2021) gave mixed results: some reported lower mortality and T-cell recovery with Tα1 in severely ill patients, others found no benefit, and a 2023 meta-analysis of 9 studies found no significant effect on mortality
- Favalli et al. (1985, Cancer Immunology, Immunotherapy) showed Tα1 given with interferon restored natural killer cell activity in mice immunosuppressed with cyclophosphamide
- Vaccine studies reported that Tα1 co-administration improved antibody responses to influenza vaccine in elderly and hemodialysis patients
- In a mouse melanoma model, Tα1 combined with an anti-PD-1 antibody led to significantly fewer lung metastases than vehicle
Thymosin Alpha-1 Dosage
- Clinical standard (Zadaxin): 1.6 mg subcutaneous injection twice weekly
- Hepatitis B/C treatment: 1.6 mg SC twice weekly for 6–12 months, often combined with interferon-alpha
- Immune enhancement/anti-aging: 1.6 mg SC twice weekly or 450 mcg daily
- Acute immune challenge (infection): 1.6 mg daily for 7–14 days, then reduce to twice weekly
- Cancer adjunct therapy: 1.6 mg SC twice weekly, ongoing, in combination with standard oncology protocols
- Vaccine adjuvant: 1.6 mg SC on the day of and 7 days after vaccination to enhance immune response
- Inject subcutaneously in the upper arm, abdomen, or thigh; rotate sites
- No food timing restrictions
- Cycle: can be used continuously for chronic conditions; for wellness, 3 months on, 1 month off is common
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
Thymosin Alpha-1 Side Effects & Safety
Known Side Effects
- Well tolerated in clinical trials, with adverse event rates similar to placebo
- Injection site reactions (redness, mild pain)
- Transient low-grade fever or flu-like symptoms in some patients, typically after first few doses (sign of immune activation)
- Rare: mild fatigue or malaise in the first week
- No immunosuppression, myelosuppression, or organ toxicity reported
- No significant laboratory abnormalities in clinical trials
- Allergic reactions are extremely rare
Safety Profile
Thymosin Alpha-1 has been well tolerated in clinical trials. It is approved in more than 35 countries but not in the United States, and large placebo-controlled trials found adverse event rates similar to placebo. The FDA has said compounded Tα1 may pose a risk of immunogenicity and that the safety information on it is inadequate. Published trials have not linked Tα1 to immunosuppression or organ toxicity, though a 2026 case report described multi-organ immune-related adverse events in a patient given Tα1 together with a PD-1 inhibitor. Unlike interferon, it does not cause depression, flu-like symptoms (beyond mild transient effects), or myelosuppression. Unlike IL-2, it does not cause vascular leak syndrome. Contraindications: organ transplant recipients on immunosuppressive therapy (theoretical risk of graft rejection, though clinical data is limited). Not studied in pregnancy. Has been combined with antivirals, chemotherapy, and vaccines in clinical trials. No drug-drug interactions are established.
What to Expect
Week 1–2: Subtle effects. Some users report a mild energy boost and improved sense of well-being. A transient flu-like feeling after the first 1–2 doses is possible and indicates immune activation. Immune cell populations begin responding at the cellular level. Week 2–4: Immune function improvements become measurable in bloodwork — increased NK cell activity, normalized CD4/CD8 ratios, improved T-cell proliferative responses. Users may notice improved resistance to minor infections. Week 4–8: Full immunomodulatory effects develop. Those with chronic infections may see improved viral load or immune markers. General resistance to illness is enhanced. Recovery from exercise and stress improves as immune-mediated inflammation is better regulated. Week 8–12+: Sustained immune optimization. Patients with hepatitis may show virological improvement. Vaccine responses are enhanced. Many users report fewer sick days, faster illness recovery, and a general sense of immune resilience. Long-term use maintains these benefits. Post-discontinuation: Immune benefits persist for weeks to months but gradually diminish without ongoing thymic support.
Common Stacks
Thymogen
Thymogen (Glu-Trp) supports thymic T-cell differentiation at a basic level, while Tα1 provides comprehensive immune modulation — the combination covers multiple levels of immune regulation
LL-37
LL-37 provides direct antimicrobial activity and innate immune stimulation, complementing Tα1's adaptive immune enhancement for broad-spectrum immune defense
BPC-157
BPC-157 modulates inflammation and tissue repair through nitric oxide and growth factor pathways, working synergistically with Tα1's immune-balancing effects during recovery from illness or surgery
Epitalon
Epitalon supports telomere maintenance and thymic function restoration in aging, potentially enhancing Tα1's effects by improving the thymic microenvironment
Storage & Handling
Store lyophilized Thymosin Alpha-1 at 2–8°C for up to 24 months. For long-term storage (>1 year), -20°C is recommended. Zadaxin (commercial product) should be stored at 2–25°C per manufacturer guidelines. Reconstitute with provided sterile water or bacteriostatic water. Reconstituted solution: use immediately for Zadaxin; compounded Tα1 can be stored at 2–8°C for up to 14–21 days. Protect from light. Do not freeze reconstituted solution.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Wu J, Pei F, Zhou L, et al. The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025.
- Naing C, Ni H, Aung HH, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026.
- Mao HY, Shi TD. Treatment with interferon and thymosin alpha-1 versus interferon monotherapy for HBeAg positive chronic hepatitis B: a meta-analysis. Zhonghua Gan Zang Bing Za Zhi. 2011.
- Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009.
- Ciancio A, Andreone P, Kaiser S, et al. Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role? J Viral Hepat. 2012.
- Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. 2004.
- Shang W, Zhang B, Ren Y, et al. Thymosin alpha1 use in adult COVID-19 patients: A systematic review and meta-analysis on clinical outcomes. Int Immunopharmacol. 2023.
- Liu Y, Pan Y, Hu Z, et al. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. Clin Infect Dis. 2020.
- Gish RG, Gordon SC, Nelson D, et al. A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatol Int. 2009.
- Tuthill C, Rios I, De Rosa A, et al. Thymosin α1 continues to show promise as an enhancer for vaccine response. Ann N Y Acad Sci. 2012.
- Dinetz E, Lee E. Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials. Altern Ther Health Med. 2024.
- King RS, Tuthill C. Evaluation of thymosin α 1 in nonclinical models of the immune-suppressing indications melanoma and sepsis. Expert Opin Biol Ther. 2015.
- Favalli C, Jezzi T, Mastino A, et al. Modulation of natural killer activity by thymosin alpha 1 and interferon. Cancer Immunol Immunother. 1985.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026.
Related Peptides
Track Thymosin Alpha-1 in Your Protocol
Log your Thymosin Alpha-1 doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free